Chemical Structure
Inhibitor
New
890 Citations
Cabozantinib
BT-0015
Cabozantinib is a multi-target tyrosine kinase inhibitor targeting MET, VEGFR2, and RET, approved for renal cell carcinoma and hepatocellular carcinoma.
Biological Activity
Blocks angiogenesis, tumor growth, and metastasis by inhibiting multiple receptor tyrosine kinases.
Product Specifications
CAS Number849217-68-1
Molecular FormulaC28H24FN3O5
Molecular Weight501.51 g/mol
TargetMET, VEGFR2, RET
PathwayVEGF Signaling
Disease AreaCancer
IC50/EC50/KdIC50: 1.2 nM (VEGFR2), 0.7 nM (MET)
Purity>99%
SolubilityDMSO: ≥10 mg/mL
Storage-20°C, desiccated
SpeciesHuman
Available Sizes
| Size | Price | |
|---|---|---|
| 10 mg | $75.00 | |
| 50 mg | $265.00 |